A Clinical and Experimental Study of Isuprel in Spontaneous and Induced Asthma

Lowell, Francis C.; Curry, John J.; Schiller, Irving W.

doi:10.1056/nejm194901132400201

Cited by 27 publications

(12 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The short action of isoprenaline reported above confirms the observations of Lowell, Curry, and Schiller (1949), and of Bresnick, Beakey, Levinson, and Segal (1949), who conducted spasmogen challenge experiments after the administration of oral, parenteral, and aerosol isoprenaline. Rapid metabolic inactivation of isoprenaline can be observed in sputum (expectorated a few minutes after isoprenaline inhalations) in which the pink-brown adrenochrome derivates are sometimes mistaken for blood.…”

Section: Discussionsupporting

confidence: 85%

Variation of Drug Action on Airway Obstruction in Man

Altounyan¹,

Patterson²

1967

Survey of Anesthesiology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 85%

Variation of Drug Action on Airway Obstruction in Man

Altounyan¹,

Patterson²

1967

Survey of Anesthesiology

View full text Add to dashboard Cite

“…The role of long-acting β agonist (LABA) drugs in asthma mortality represents the latest chapter in a long running debate about the safety of inhaled β agonist drugs in the treatment of asthma 1 2 3 4 5 6 7 8 9 10. Evidence for a possible increased risk of asthma mortality with LABA therapy was first raised in 1993 with publication of the Salmeterol Nationwide Surveillance Study (SNS) 9.…”

mentioning

confidence: 99%

Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy

Weatherall

Wijesinghe

Perrin

et al. 2009

Thorax

113

View full text Add to dashboard Cite

Background: There is concern that long-acting b agonist (LABA) drugs may increase the risk of asthma mortality. Methods: A meta-analysis was conducted of asthma deaths in randomised controlled clinical trials from the GlaxoSmithKline database that compared salmeterol with a non-LABA comparator treatment in asthma. The Peto one-step method was used to determine the risk overall (all studies) and in derived datasets based on inhaled corticosteroid (ICS) use. Results: There were 35 asthma deaths in 215 studies with 106 575 subjects. Two studies (SMART and SNS) contributed 30/35 (86%) asthma deaths, the overall findings largely reflecting the characteristics of these studies. The odds ratio for risk of asthma mortality with salmeterol was 2.7 (95% CI 1.4 to 5.3). In 54 placebo controlled studies the risk of death from asthma in patients not prescribed ICS was 7.3 (95% CI 1.8 to 29.4). In 127 studies in which patients were prescribed ICS, the risk of asthma death was 2.1 (95% CI 0.6 to 7.9). In 63 studies in which patients were randomised to receive the combination salmeterol/fluticasone propionate inhaler or ICS, there were no asthma deaths among 22 600 patients. Conclusions: Salmeterol monotherapy in asthma increases the risk of asthma mortality and this risk is reduced with concomitant ICS therapy. There is no evidence that combination salmeterol/fluticasone propionate therapy is associated with an increased risk of asthma mortality, although this interpretation is limited by the low statistical power of available studies.The role of long-acting b agonist (LABA) drugs in asthma mortality represents the latest chapter in a long running debate about the safety of inhaled b agonist drugs in the treatment of asthma. 1-10Evidence for a possible increased risk of asthma mortality with LABA therapy was first raised in 1993 with publication of the Salmeterol Nationwide Surveillance Study (SNS).9 This study reported a statistically non-significant threefold increased risk of death in subjects treated with salmeterol compared with regular salbutamol, but no increase in hospital admissions or life-threatening events. These findings led to the Salmeterol Multicentre Asthma Research Trial (SMART), which reported a statistically significant fourfold increase in asthma mortality with salmeterol compared with placebo.10 In subgroup analyses, there was no increased risk in asthma mortality for salmeterol in subjects prescribed concomitant ICS therapy. Although limited by low power, this finding raised the possibility that the mortality risk was restricted to salmeterol as monotherapy and that concomitant use of ICS therapy may protect against the risk.This interpretation was supported by the findings of the large UK-based case-control study in which there was no evidence of any positive association between LABAs and asthma death. 11As almost all patients in the UK during the period of the study who were prescribed LABA therapy were co-prescribed ICS therapy, 12 these findings provided evidence that the use of LABAs with c...

show abstract

“…7 After {j-receptors were further subdivided into f1r and f12-receptors, 8 more selective inhaled f12-agents were dev, eloped, including albuterol, bitolterol, fenoterol, metaproterenol, pirbuterol, salmeterol, terbutaline, and others. Albuterol became the most popular f12-agonist in this country.…”

mentioning

confidence: 99%

The Combination of Ipratropium and Albuterol Is More Effective Than Either Agent Alone

Petty

1995

Chest

View full text Add to dashboard Cite

A Clinical and Experimental Study of Isuprel in Spontaneous and Induced Asthma

Cited by 27 publications

References 5 publications

Variation of Drug Action on Airway Obstruction in Man

Variation of Drug Action on Airway Obstruction in Man

Meta-analysis of the risk of mortality with salmeterol and the effect of concomitant inhaled corticosteroid therapy

The Combination of Ipratropium and Albuterol Is More Effective Than Either Agent Alone

Contact Info

Product

Resources

About